Building a CAR-T CMC Strategy on a Limited Budget

• by Kate Fynes

• October 6, 2026

Correction to “Combined inhibition of de novo pyrimidine synthesis and ATR promotes ATF4-mediated cell death in TP53-deficient ALL”

• October 5, 2026

Thyroid Cancer: What Are the Latest Advances in Treatment?

Thyroid cancer is usually a highly treatable malignancy with overall five-year survival rates over 98%. Many patients with thyroid cancer go on to live for several decades after their disease is cured. 

• by

• September 29, 2026

• 6 min

A platform of serially transplantable AML PDX models covering subgroups for which no cell lines exist

• by Binje Vick, Vindi Jurinovic, Kristina Kuhbandner, Lena Lagally, Lisa Latzko, Chiara Arnreich, Gerulf Hänel, Amelie Muth, Maximilian Schönung, Arnold Kloos, Maja Rothenberg-Thurley, Annika M. Dufour, Stephanie Schneider, Lesca M. Holdt, Liliana Mura, Fabian Klein, Annette Frank, Dhruv Mehra, Annika Fröhlich, Johannes W. Bagnoli, Maya C. André, Claudia D. Baldus, Martin Carroll, Christine Dierks, Martin Ebinger, Katharina S. Götze, Pablo Menéndez, Christian Récher, Ambrine Sahal, Jean-Emmanuel Sarry, Christian Thiede, Talía Velasco-Hernández, Xiaoyan Wei, Jan H. Klusmann, Wolfgang Enard, Michael von Bergwelt-Baildon, Wolfgang Hiddemann, Klaus H. Metzeler, Philipp A. Greif, Michael Heuser, Daniel B. Lipka, Marion Subklewe, Sebastian Vosberg, Tobias Herold, Karsten Spiekermann, Irmela Jeremias

• October 5, 2026